AstraZeneca’s Asthma Study: Key Insights for Investors

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIIb clinical study titled ‘Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA).' The study aims to compare the effect of a budesonide/albuterol metered-dose inhaler (BDA MDI) with an albuterol sulfate metered-dose inhaler (AS MDI) on the rate of severe asthma exacerbations in adolescents with a history of asthma exacerbations.

The interventions being tested include the BDA MDI, which combines budesonide and albuterol for oral inhalation, and the AS MDI, which contains albuterol sulfate. Both are administered as needed to manage asthma symptoms.

This randomized, double-blind, multicenter study follows a parallel-group design. Participants are randomly assigned to either the experimental BDA MDI group or the active comparator AS MDI group, with both participants and investigators masked to the treatment allocation. The primary purpose of the study is treatment-focused.

The study began on May 20, 2024, with primary completion expected within 52 weeks, and the last update was submitted on August 14, 2025. These dates indicate the study’s progression and provide a timeline for potential data availability.

The outcome of this study could significantly impact AstraZeneca’s market position, as successful results may enhance investor confidence and influence stock performance positively. The study’s findings may also affect competitive dynamics in the asthma treatment market.

The study is currently ongoing, with further details available on the ClinicalTrials portal.